Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04713657 · ClinicalTrials.gov registry record · Phase 1
Beta-blocker Administration for Cardiomyocyte Division
A Phase 1 study of Tetralogy of Fallot and Double Outlet Right Ventricle, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT04713657 is a Phase 1 study of Tetralogy of Fallot and Double Outlet Right Ventricle that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 40 participants, below the 184-participant average among 7 other Tetralogy of Fallot trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04713657, a Phase 1 study of Tetralogy of Fallot and Double Outlet Right Ventricle, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
Heart failure is a common long-term complication in patients with congenital heart disease (CHD). Medical treatments to promote regeneration of new healthy heart muscle cells have the potential to provide new heart failure treatments for these patients. The development of such therapies is limited by the poor understanding of the ways in which heart muscles grow after birth. Investigators have learned that humans without heart disease generate new heart muscles cells up to the age of 20 years old and that this is decreased in patients with congenital heart disease like Tetralogy of Fallot. Investigators are trying to determine if treatment with a medicine called Propranolol can increase heart muscle cell proliferation and, with that, normalize heart growth. Investigators will examine discarded heart muscle tissue that is obtained during surgery for the presence of new heart muscle cells. Propranolol is approved by the Food and Drug Administration (FDA) to treat a certain kind of benign tumor in infants (hemangioma), but it is not currently approved by the FDA to increase heart muscle growth.
Conditions Studied
Interventions
- OTHER Urine Collection
- PROCEDURE Echocardiogram
- DRUG Propranolol Hydrochloride
- OTHER N-thymidine
- PROCEDURE Cardiac MRI (CMR)
Study Locations (3)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Upmc Children'S Hospital of Pittsburgh - Pittsburgh
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04713657
The ClinicalTrials.gov registry entry for NCT04713657 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 7 other Tetralogy of Fallot trials with a reported enrollment target (78% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tetralogy of Fallot appearing as the primary indexed condition, and to 5 interventions - of which Urine Collection is the first listed.
NCT04713657 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, New York.
Frequently Asked Questions
What is clinical trial NCT04713657 about?
NCT04713657 is a clinical study titled "Beta-blocker Administration for Cardiomyocyte Division". Heart failure is a common long-term complication in patients with congenital heart disease (CHD). Medical treatments to promote regeneration of new healthy heart muscle cells have the potential to provide new heart failure treatments for these patients. The development of such therapies is limited b...
What is the current status of trial NCT04713657?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-12-16. Estimated completion is 2030-12-31.
What conditions does trial NCT04713657 study?
This clinical trial studies the following conditions: Tetralogy of Fallot, Double Outlet Right Ventricle.
What interventions are being tested in trial NCT04713657?
The interventions under investigation include: Urine Collection (OTHER), Echocardiogram (PROCEDURE), Propranolol Hydrochloride (DRUG), N-thymidine (OTHER), Cardiac MRI (CMR) (PROCEDURE).
Who is sponsoring clinical trial NCT04713657?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04713657 being conducted?
This trial has 3 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tetralogy of Fallot
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD
COMPLETED · Phase 1
-
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases
RECRUITING
-
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development
RECRUITING
-
ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent
ACTIVE NOT RECRUITING · NA
-
Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction
ACTIVE NOT RECRUITING · NA
-
ALTERRA Post-Approval Study
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.